Analyst Price Target is $102.67
▼ -2.90% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for DaVita in the last 3 months. The average price target is $102.67, with a high forecast of $113.00 and a low forecast of $90.00. The average price target represents a -2.90% upside from the last price of $105.73.
Current Consensus is
The current consensus among 4 contributing investment analysts is to moderate buy stock in DaVita. This Moderate Buy consensus rating has held steady for over two years.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.